PURPOSE: The rationale for hypofractionated radiotherapy in the treatment of @entity263 is based on the modern understanding of radiobiology and advances in stereotactic body radiotherapy (SBRT) techniques. Whole-pelvis irradiation combined with SBRT boost for high-risk @entity263 might escalate biologically effective dose without increasing @entity137 . Here, we report our 4-year results of SBRT boost for high-risk @entity263 . METHODS AND MATERIALS: From October 2009 to August 2012, 41 @entity1 newly diagnosed, high-risk or very high-risk (NCCN definition) @entity263 were treated with whole-pelvis irradiation and SBRT boost. The whole pelvis dose was 45   Gy (25 fractions of 1.8   Gy). The SBRT boost dose was 21   Gy (three fractions of 7   Gy). Ninety percent of these @entity1 received hormone therapy. The @entity137 of @entity344 were scored by Common @entity137 Criteria Adverse Effect (CTCAE v3.0). Biochemical failure was defined by Phoenix definition. RESULTS: Median follow-up was 42   months. Mean PSA before treatment was 44.18   ng/ml. Mean PSA level at 3, 6, 12, 18, and 24   months was 0.94, 0.44, 0.13, 0.12, and 0.05   ng/ml, respectively. The estimated 4-year biochemical failure-free survival was 91.9%. Three biochemical failures were observed. GI and GU tract @entity137 were minimal. No grade 3 acute GU or @entity344 was noted. During radiation therapy, 27% of the @entity1 had grade 2 acute GU @entity137 and 12% had grade 2 acute @entity344 . At 3   months, most @entity137 scores had returned to baseline. At the last follow-up, there was no grade 3 late GU or @entity344 . CONCLUSIONS: Whole-pelvis irradiation combined with SBRT boost for high-risk @entity263 is feasible with minimal @entity137 and encouraging biochemical failure-free survival. Continued accrual and follow-up would be necessary to confirm the biochemical control rate and the @entity137 profiles.

The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'toxicities'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'prostate cancer'] @entity344 :: ('MESH:D005767', 'Disease') :: ['GI toxicity', 'gastrointestinal (GI) and genitourinary (GU) tracts']
@entity263 :: (MESH:D011471,Disease) :: ['localized prostate cancer']
